Bio-Path (BPTH) 10-Q14 Nov 222022 Q3 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2022	Nov. 09, 2022
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-36333
Entity Registrant Name	BIO-PATH HOLDINGS INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-0652870
Entity Address, Address Line One	4710 Bellaire Boulevard, Suite 210
Entity Address, City or Town	Bellaire
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77401
City Area Code	832
Local Phone Number	742-1357
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	BPTH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		7,960,164
Entity Central Index Key	0001133818
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash	$ 13,650	$ 23,774
Prepaid drug product	2,347	523
Other current assets	2,140	1,843
Total current assets	18,137	26,140
Fixed assets
Furniture, fixtures & equipment	1,120	1,099
Less accumulated depreciation	(939)	(874)
Furniture, fixtures & equipment, net	181	225
Right of use operating assets	221	203
Total Assets	18,539	26,568
Current liabilities
Accounts payable	1,046	106
Accrued expenses	1,050	770
Current portion of lease liabilities	105	82
Total current liabilities	2,201	958
Noncurrent lease liabilities	141	153
Total Liabilities	2,342	1,111
Shareholders' equity
Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding
Common stock, $.001 par value; 200,000 shares authorized; 7,160 and 7,160 shares issued and outstanding, respectively	7	7
Additional paid in capital	103,753	103,111
Accumulated deficit	(87,563)	(77,661)
Total shareholders' equity	16,197	25,457
Total Liabilities & Shareholders' Equity	$ 18,539	$ 26,568

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Thousands	Sep. 30, 2022	Dec. 31, 2021
CONSOLIDATED BALANCE SHEETS
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	10,000	10,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	200,000	200,000
Common Stock, shares issued	7,160	7,160
Common Stock, shares outstanding	7,160	7,160

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses
Research and development	$ 2,353	$ 981	$ 6,302	$ 3,002
General and administrative	1,193	1,088	3,613	3,324
Total operating expenses	3,546	2,069	9,915	6,326
Net operating loss	(3,546)	(2,069)	(9,915)	(6,326)
Other income
Interest income	11		13	2
Total other income	11		13	2
Net loss	$ (3,535)	$ (2,069)	$ (9,902)	$ (6,324)
Net loss per share, basic (in dollars per share)	$ (0.49)	$ (0.29)	$ (1.38)	$ (0.96)
Net loss per share, diluted (in dollars per share)	$ (0.49)	$ (0.29)	$ (1.38)	$ (0.96)
Weighted average number of common shares outstanding, basic (in shares)	7,160	7,038	7,160	6,578
Weighted average number of common shares outstanding, diluted (in shares)	7,160	7,038	7,160	6,578

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flow from operating activities
Net loss	$ (9,902)	$ (6,324)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation	642	591
Amortization of right of use assets	67	63
Depreciation	65	56
(Increase) decrease in operating assets
Prepaid drug product	(1,824)	(840)
Other current assets	(297)	(591)
Increase (decrease) in operating liabilities
Accounts payable and accrued expenses	1,220	(1)
Lease liabilities	(74)	(70)
Net cash used in operating activities	(10,103)	(7,116)
Cash flow from investing activities
Purchases of furniture, fixtures & equipment	(21)	(47)
Net cash used in investing activities	(21)	(47)
Cash flow from financing activities
Net proceeds from sale of common stock		15,852
Net proceeds from exercise of warrants		4,157
Net cash provided by financing activities		20,009
Net (decrease) increase in cash	(10,124)	12,846
Cash, beginning of period	23,774	13,755
Cash, end of period	13,650	$ 26,601
Non-cash operating activities
Right of use asset recognized in exchange for lease obligation	$ 85

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Common Stock	Additional Paid in Capital.	Accumulated Deficit	Total
Beginning Balance at Dec. 31, 2020	$ 5	$ 82,286	$ (67,221)	$ 15,070
Beginning Balance (in shares) at Dec. 31, 2020	4,542
Issuance of common stock, net of fees	$ 2	15,850		15,852
Issuance of common stock, net of fees (in shares)	2,189
Exercise of warrants, net of fees		4,157		4,157
Exercise of warrants, net of fees (in shares)	429
Stock-based compensation		591		591
Net loss			(6,324)	(6,324)
Ending Balance at Sep. 30, 2021	$ 7	102,884	(73,545)	29,346
Ending Balance (in shares) at Sep. 30, 2021	7,160
Beginning Balance at Jun. 30, 2021	$ 7	101,223	(71,476)	29,754
Beginning Balance (in shares) at Jun. 30, 2021	6,960
Issuance of common stock, net of fees		1,399		1,399
Issuance of common stock, net of fees (in shares)	200
Stock-based compensation		262		262
Net loss			(2,069)	(2,069)
Ending Balance at Sep. 30, 2021	$ 7	102,884	(73,545)	29,346
Ending Balance (in shares) at Sep. 30, 2021	7,160
Beginning Balance at Dec. 31, 2021	$ 7	103,111	(77,661)	25,457
Beginning Balance (in shares) at Dec. 31, 2021	7,160
Stock-based compensation		642		642
Net loss			(9,902)	(9,902)
Ending Balance at Sep. 30, 2022	$ 7	103,753	(87,563)	16,197
Ending Balance (in shares) at Sep. 30, 2022	7,160
Beginning Balance at Jun. 30, 2022	$ 7	103,541	(84,028)	19,520
Beginning Balance (in shares) at Jun. 30, 2022	7,160
Stock-based compensation		212		212
Net loss			(3,535)	(3,535)
Ending Balance at Sep. 30, 2022	$ 7	$ 103,753	$ (87,563)	$ 16,197
Ending Balance (in shares) at Sep. 30, 2022	7,160

Organization and Business

Organization and Business	9 Months Ended
Organization and Business	Sep. 30, 2022
Organization and Business
Organization and Business	1. Organization and Business The Company is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The Company’s drug delivery and antisense technology, called DNAbilize®, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, In vivo, The Company was incorporated in May 2000 as a Utah corporation. In February 2008, Bio-Path Subsidiary completed a reverse merger with the Company, which at the time was traded over the counter and had no current operations. The prior name of the Company was changed to Bio-Path Holdings, Inc. and the directors and officers of Bio-Path Subsidiary became the directors and officers of Bio-Path Holdings, Inc. Effective December 31, 2014, the Company changed its state of incorporation from Utah to Delaware through a statutory conversion pursuant to the Utah Revised Business Corporation Act and the Delaware General Corporation Law. The Company’s operations to date have been limited to organizing and staffing the Company, acquiring, developing and securing its technology and undertaking product development for a limited number of product candidates. As the Company has not begun its planned principal operations of commercializing a product candidate, the Company’s activities are subject to significant risks and uncertainties, including the potential requirement to secure additional funding, the outcome of the Company’s clinical trials and failing to operationalize the Company’s current drug candidates before another company develops similar products.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
Significant Accounting Policies	Sep. 30, 2022
Significant Accounting Policies
Significant Accounting Policies	2. Significant Accounting Policies Net Loss Per Share – per share for 2021 did not include 485,908 shares and 429,791 shares issuable pursuant to the exercise of outstanding common stock options and warrants, respectively, as of September 30, 2021 as the effect would be antidilutive. Fair Value -

Prepaid Drug Product

Prepaid Drug Product	9 Months Ended
Prepaid Drug Product	Sep. 30, 2022
Prepaid Drug Product
Prepaid Drug Product	3. Prepaid Drug Product Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future clinical development activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed. The Company recognized certain expenses and incurred installment costs for its contract drug manufacturing and raw material suppliers with prepayments totaling $0.5 million as of December 31, 2021 pursuant to drug supply contracts for the manufacture and delivery of prexigebersen for testing in a Phase 2 clinical trial and BP1002 for testing in a Phase 1 clinical trial. The Company recognized certain expenses and incurred additional installment costs during the first nine months of 2022, with advanced payments remaining to be expensed totaling $2.3 million as of September 30, 2022.

Other Current Assets

Other Current Assets	9 Months Ended
Other Current Assets	Sep. 30, 2022
Other Current Assets
Other Current Assets	4. Other Current Assets As of September 30, 2022, other current assets included prepaid expenses of $2.1 million, comprised primarily of prepayments of $1.6 million made for the Company’s clinical trials for BP1002 in separate clinical trials for lymphoma and AML, prexigebersen in AML as well as BP1001-A in solid tumors. Additionally, the Company had prepaid insurance expenses of $0.5 million. As of December 31, 2021, other current assets included prepaid expenses of $1.8 million, comprised primarily of prepayments of $1.4 million made for the Company’s clinical trials for BP1002 in AML and lymphoma, prexigebersen in AML and BP1001-A in solid tumors as well as prepaid insurance of $0.3 million and other prepaid expenses of $0.1 million.

Accounts Payable

Accounts Payable	9 Months Ended
Accounts Payable	Sep. 30, 2022
Accounts Payable
Accounts Payable	5. Accounts Payable As of September 30, 2022, current liabilities included accounts payable of $1.0 million, comprised primarily of amounts owed for clinical trial expenses of $0.4 million, drug supply manufacturing of $0.4 million and legal and patent fees of $0.2 million. As of December 31, 2021, current liabilities included accounts payable of $0.1 million, comprised primarily of legal and patent fees and expenses related to manufacturing totaling $0.1 million.

Accrued Expense

Accrued Expense	9 Months Ended
Accrued Expense	Sep. 30, 2022
Accrued Expense
Accrued Expense	6. Accrued Expense As of September 30, 2022, current liabilities included accrued expenses of $1.1 million, comprised primarily of manufacturing and testing services of $0.5 million, accrued employee vacation and bonus expenses of $0.3 million, professional and consulting fees of $0.1 million, legal and patent fees of $0.1 million and other accrued expenses of $0.1 million. As of December 31, 2021, current liabilities included accrued expenses of $0.8 million, comprised primarily of accrued employee vacation and bonus expenses of $0.4 million, franchise tax expense of $0.1 million, legal and patent fees of $0.1 million, manufacturing expenses of $0.1 million and other accrued expenses of $0.1 million.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2022
Stockholders' Equity
Stockholders' Equity	7. Stockholders’ Equity Issuances of Common Stock - On February 16, 2021, the Company entered into a placement agency agreement with Roth Capital Partners, LLC relating to a public offering of At-The-Market Offering Agreement Company may offer and sell, from time to time, through or to Wainwright, shares of the Company’s common stock. From July 14, 2020 to August 18, 2021, offers and any applicable sales of shares of common stock under the Offering Agreement were made pursuant to the base prospectus contained in the 2019 Shelf Registration Statement and a related prospectus supplement filed with the SEC on July 14, 2020, for an aggregate offering price of up to $7.0 million. From August 19, 2021 to June 14, 2022, offers and any applicable sales of shares of common stock under the Offering Agreement were made pursuant to the base prospectus contained in the 2019 Shelf Registration Statement and a related prospectus supplement filed with the SEC on August 19, 2021, as amended pursuant to an amendment to prospectus supplement filed with the SEC on March 15, 2022, for an aggregate offering price of up to $10.0 million. From and after June 15, 2022, offers and sales of shares of common stock under the Offering Agreement may be made pursuant to the Company’s shelf registration statement on Form S-3, which was declared effective by the SEC on June 14, 2022 (File No. 333-265282) (the “2022 Shelf Registration Statement”), and a related prospectus supplement filed with the SEC on June 14, 2022, as supplemented and amended pursuant to a prospectus supplement filed with the SEC on July 29, 2022, for an aggregate offering price of up to $3.0 million, provided that the Company may be limited in the amount of securities that it can currently sell under the Offering Agreement pursuant to Instruction I.B.6 to Form S-3 for so long as its public float remains less than $75.0 million. Under the Offering Agreement, Wainwright may sell shares by any method deemed to be an “at the market” offering as defined in Rule 415 under the Securities Act of 1933, as amended. The Company will pay Wainwright a commission on the aggregate gross proceeds from each sale of shares under the Offering Agreement and has agreed to provide Wainwright with customary indemnification and contribution rights. The Company has also agreed to reimburse Wainwright for certain specified expenses. During the nine months ended September 30, 2022, the Company did not offer or sell any shares of its common stock under the Offering Agreement. Stockholders’ Equity totaled $16.2 million as of September 30, 2022 compared to $25.5 million as of December 31, 2021. There were 7,160,164 shares of common stock issued and outstanding outstanding

Stock-Based Compensation Plan

Stock-Based Compensation Plan	9 Months Ended
Stock-Based Compensation Plan	Sep. 30, 2022
Stock-Based Compensation Plan
Stock-Based Compensation Plan	8. Stock-Based Compensation Plan The 2017 Plan Stock-based compensation expense for the three months ended September 30, 2022 and 2021 was $0.2 million and $0.3 million, respectively. Of these amounts, stock-based compensation expense for personnel involved in the Company’s general and administrative activities for each of the three months ended September 30, 2022 and 2021 was $0.2 million. Stock-based compensation expense for personnel involved in the Company’s research and development activities for the three months ended September 30, 2022 and 2021 was $49,000 and $46,000, respectively. Stock-based compensation expense for each of the nine months ended September 30, 2022 and 2021 was $0.6 million. Of these amounts, stock-based compensation expense for personnel involved in the Company’s general and administrative activities for each of the nine months ended September 30, 2022 and 2021 was $0.5 million. Stock-based compensation expense for personnel involved in the Company’s research and development activities for each of the nine months ended September 30, 2022 and 2021 was $0.1 million. The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock options granted, with the following weighted-average assumptions for options granted in the nine months ended September 30, 2022 and 2021, respectively: 2022 2021 Risk-free interest rate 2.43 % 1.15 % Expected volatility 127 % 128 % Expected term in years 6.0 6.0 Dividend yield — % — % The following summary represents option activity under the Company’s stock-based compensation plans for the nine months ended September 30, 2022: Weighted- Average Exercise Options Price (in thousands) Outstanding at December 31, 2021 486 $ 14.58 Granted 192 3.71 Forfeited (2) 7.02 Expired (18) 5.96 Outstanding at September 30, 2022 658 $ 11.67 Vested and expected to vest September 30, 2022 629 $ 11.96 Exercisable at September 30, 2022 289 $ 19.99 As of September 30, 2022, outstanding stock options did not have any aggregate intrinsic value. The aggregate intrinsic value represents the total pretax intrinsic value (the difference between the Company’s closing stock price on September 30, 2022 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on September 30, 2022. This amount changes based on the fair value of the Company’s stock. As of September 30, 2022, unamortized stock-based compensation expense for all outstanding options was $1.5 million, which is expected to be recognized over a weighted average vesting period of 2.4 years.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2022
Commitments and Contingencies
Commitments and Contingencies	9. Commitments and Contingencies Drug Supplier Project Plan

Subsequent Events

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2022
Subsequent Events
Subsequent Events	10. Subsequent Event 2022 Registered Direct Offering and 2022 Private Placement

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2022
Significant Accounting Policies
Net Loss Per Share	Net Loss Per Share – per share for 2021 did not include 485,908 shares and 429,791 shares issuable pursuant to the exercise of outstanding common stock options and warrants, respectively, as of September 30, 2021 as the effect would be antidilutive.
Fair Value	Fair Value -

Stock-Based Compensation Plan (

Stock-Based Compensation Plan (Tables)	9 Months Ended
Stock-Based Compensation Plan (Tables)	Sep. 30, 2022
Stock-Based Compensation Plan
Summary of weighted-average assumptions	The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock options granted, with the following weighted-average assumptions for options granted in the nine months ended September 30, 2022 and 2021, respectively: 2022 2021 Risk-free interest rate 2.43 % 1.15 % Expected volatility 127 % 128 % Expected term in years 6.0 6.0 Dividend yield — % — %
Schedule of option activity under stock-based compensation plans	The following summary represents option activity under the Company’s stock-based compensation plans for the nine months ended September 30, 2022: Weighted- Average Exercise Options Price (in thousands) Outstanding at December 31, 2021 486 $ 14.58 Granted 192 3.71 Forfeited (2) 7.02 Expired (18) 5.96 Outstanding at September 30, 2022 658 $ 11.67 Vested and expected to vest September 30, 2022 629 $ 11.96 Exercisable at September 30, 2022 289 $ 19.99

Significant Accounting Polici_3

Significant Accounting Policies (Details) - shares	9 Months Ended
Significant Accounting Policies (Details) - shares	Sep. 30, 2022	Sep. 30, 2021
Warrant
Significant Accounting Policies [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	400,531	429,791
Stock Options
Significant Accounting Policies [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	657,408	485,908

Prepaid Drug Product (Details)

Prepaid Drug Product (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Prepaid Drug Product
Prepaid drug product for testing		$ 0.5
Advanced payments remaining to be expensed	$ 2.3

Other Current Assets (Details)

Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Other prepaid expenses		$ 500
Other current assets	$ 2,140	1,843
Prepaid Expenses [Member]
Other current assets	2,100	1,800
Prepaid Expenses [Member] \| BP1002 in lymphoma, prexigebersen in AML and prexigebersen-A [Member]
Other current assets	1,600	1,400
Other Prepaid Expenses [Member] \| BP1002 in lymphoma, prexigebersen in AML and prexigebersen-A [Member]
Other prepaid expenses		100
Prepaid insurance		$ 300
Prepaid expenses related to preclinical studies	$ 500

Accounts Payable (Details)

Accounts Payable (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accounts Payable [Line Items]
Accounts payable, current	$ 1,046	$ 106
Clinical trials for prexigebersen in AML and BP1002 in lymphoma [Member]
Accounts Payable [Line Items]
Accounts payable, current	400
Manufacturing Costs [Member]
Accounts Payable [Line Items]
Accounts payable, current	400
Legal and Patent [Member]
Accounts Payable [Line Items]
Accounts payable, current	$ 200	$ 100

Accrued Expense (Details)

Accrued Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accrued Expense
Accrued expense	$ 1,050	$ 770
Accrued vacation and bonus expenses	300	400
Manufacturing and testing services	500
Professional and consulting fees	100
Accrued legal and patent fees	$ 100	100
Other accrued expenses		100
Manufacturing expenses		$ 100

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ in Thousands						3 Months Ended	9 Months Ended
Stockholders' Equity (Details) - USD ($) $ in Thousands	Jul. 29, 2022	Mar. 15, 2022	Jul. 14, 2021	Feb. 18, 2021	Feb. 16, 2021	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Shareholders Equity [Line Items]
Net proceeds from sale of common stock				$ 12,200				$ 15,852
Stockholders' Equity total amount						$ 29,346	$ 16,197	$ 29,346	$ 19,520	$ 25,457	$ 29,754	$ 15,070
Common Stock, shares issued							7,160,000			7,160,000
Common Stock, shares outstanding							7,160,000			7,160,000
Preferred Stock, shares issued							0			0
Preferred Stock, shares outstanding							0			0
Common Stock
Shareholders Equity [Line Items]
Shares issued (in shares)						200,000		2,189,000
Stockholders' Equity total amount						$ 7	$ 7	$ 7	$ 7	$ 7	$ 7	$ 5
IPO [Member]
Shareholders Equity [Line Items]
Shares issued (in shares)					1,710,600
Net proceeds from sale of common stock					$ 13,000
2021 Public Offering [Member]
Shareholders Equity [Line Items]
Shares issued (in shares)					1,650,000
At-The-Market Offering Agreement [Member]
Shareholders Equity [Line Items]
Public float							75,000
Maximum aggregate offering price	$ 3,000	$ 10,000	$ 7,000
Stockholders' Equity total amount							$ 16,200			$ 25,500
At-The-Market Offering Agreement [Member] \| Common Stock
Shareholders Equity [Line Items]
Common Stock, shares issued							7,160,164
Common Stock, shares outstanding							7,160,164
At-The-Market Offering Agreement [Member] \| Preferred Stock
Shareholders Equity [Line Items]
Preferred Stock, shares issued							0
Preferred Stock, shares outstanding							0

Stock-Based Compensation Plan -

Stock-Based Compensation Plan - Weighted Average Assumptions (Details)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Stock-Based Compensation Plan
Risk-free interest rate	2.43%	1.15%
Expected volatility	127%	128%
Expected term in years	6 years	6 years
Dividend yield	0%	0%

Stock-Based Compensation Plan_2

Stock-Based Compensation Plan - Option Activity Under Plan (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Stock-Based Compensation Plan
Outstanding \| shares	486
Granted \| shares	192
Forfeited \| shares	(2)
Expired \| shares	(18)
Outstanding \| shares	658
Vested and expected to vest \| shares	629
Exercisable \| shares	289
Weighted-Average Exercise Price, Outstanding \| $ / shares	$ 14.58
Weighted-Average Exercise Price, Granted \| $ / shares	3.71
Weighted-Average Exercise Price, Forfeited \| $ / shares	7.02
Weighted-Average Exercise Price, Expired \| $ / shares	5.96
Weighted-Average Exercise Price, Outstanding \| $ / shares	11.67
Weighted - Average Exercise Price, Vested and expected to vest \| $ / shares	11.96
Weighted-Average Exercise Price, Exercisable \| $ / shares	$ 19.99

Stock-Based Compensation Plan_3

Stock-Based Compensation Plan - Narrative (Details) - USD ($)		3 Months Ended		9 Months Ended		21 Months Ended
	Dec. 19, 2019	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022
Stock Based Compensation Plans [Line Items]
Stock-based compensation expense		$ 200,000	$ 300,000			$ 600,000
Unamortized stock-based compensation expense for outstanding options		1,500,000		$ 1,500,000		$ 1,500,000
Weighted average vesting period				2 years 4 months 24 days
Stock Incentive Plan 2017 [Member]
Stock Based Compensation Plans [Line Items]
Increase in number of shares reserved for grant	600,000
Number of shares reserved for grant and issuance	660,000
Expiration period (in years)				10 years
Research and Development Expense [Member]
Stock Based Compensation Plans [Line Items]
Stock-based compensation expense		49,000	46,000	$ 100,000	$ 100,000
General and Administrative Expense [Member]
Stock Based Compensation Plans [Line Items]
Stock-based compensation expense		$ 200,000	$ 200,000	$ 500,000	$ 500,000

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	9 Months Ended
Commitments and Contingencies (Details) $ in Millions	Sep. 30, 2022 USD ($)
Product Liability Contingency [Line Items]
Other commitments, due in next twelve months	$ 5
Drug Supplier Project Plan [Member]
Product Liability Contingency [Line Items]
Other commitments	$ 5
Term commitments are incurred	12 months
Manufacture of Drug Substance [Member]
Product Liability Contingency [Line Items]
Other commitments	$ 2.4
Manufacturer of Prexigebersen [Member]
Product Liability Contingency [Line Items]
Other commitments	1.8
Manufacturing Development [Member]
Product Liability Contingency [Line Items]
Other commitments	0.6
Testing Services [Member]
Product Liability Contingency [Line Items]
Other commitments	$ 0.2

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Thousands				9 Months Ended
Subsequent Events (Details) - USD ($) $ in Thousands	Nov. 09, 2022	Nov. 06, 2022	Feb. 18, 2021	Sep. 30, 2021
Subsequent Event [Line Items]
Gross proceeds			$ 12,200	$ 15,852
Subsequent Event [Member] \| Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Shares issued (in shares)		800,000
Gross proceeds		$ 2,000
Subsequent Event [Member] \| Private Placement [Member]
Subsequent Event [Line Items]
Shares available for purchase from warrants issued	800,000
Net proceeds	$ 1,700